Compare Amgen, Inc. (AMGN) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Newmont Corporation — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Newmont Corporation trades at $94.11 (market cap $101.73B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NEM | |
|---|---|---|
Market Cap | $196.12B | $101.73B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $131.95 |
52-Week Low | $271.18 | $57.35 |
Enterprise Value | $241.41B | $98.48B |
Dividend Yield | 2.77% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Newmont Corporation (NEM) trades at $95.29, up 0.51% with bearish technical signals but strong fundamentals. The gold miner reported record Q1 2026 earnings of $2.90 EPS, beating estimates by 40%, with revenue growth accelerating to 46% year-over-year. Analyst consensus remains strongly bullish with 75% buy ratings and a $141 price target representing 48% upside. Cash flow generation reached $3.1 billion in Q1, supporting dividend payments and debt reduction.
Despite gold price volatility creating near-term pressure, Newmont's operational excellence and margin expansion support long-term value. The stock trades at attractive valuations (P/E 12.4x) with 34% net margins, though exposure to commodity cycles and recent technical weakness require careful risk management. The upcoming Q2 earnings on July 23 will be critical for confirming the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
